Forest’s Sigh Of Relief: Aerospan Is Approved
This article was originally published in The Pink Sheet Daily
Forest receives approval on Jan. 27 for a non-CFC formulation of its asthma therapy Aerobid.
You may also be interested in...
FDA's final rule sets a deadline one year earlier than the latest possible date suggested in the proposed rule. Manufacturers have said that once a phase-out date was set they could build sufficient supply of ozone-friendly albuterol product within 18 months.
Forest does not expect a near-term approval for Aerospan (flunisolide), a non-CFC formulation of its asthma therapy Aerobid
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue